JPH0436159A - Royal jelly-containing soft capsule - Google Patents
Royal jelly-containing soft capsuleInfo
- Publication number
- JPH0436159A JPH0436159A JP2142746A JP14274690A JPH0436159A JP H0436159 A JPH0436159 A JP H0436159A JP 2142746 A JP2142746 A JP 2142746A JP 14274690 A JP14274690 A JP 14274690A JP H0436159 A JPH0436159 A JP H0436159A
- Authority
- JP
- Japan
- Prior art keywords
- royal jelly
- wax
- soft capsule
- content
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940109850 royal jelly Drugs 0.000 title claims description 67
- 239000007901 soft capsule Substances 0.000 title claims description 24
- 108010010803 Gelatin Proteins 0.000 claims abstract description 10
- 239000008273 gelatin Substances 0.000 claims abstract description 10
- 229920000159 gelatin Polymers 0.000 claims abstract description 10
- 235000019322 gelatine Nutrition 0.000 claims abstract description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 8
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 claims abstract description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011575 calcium Substances 0.000 claims abstract description 7
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000003278 egg shell Anatomy 0.000 claims abstract description 4
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 4
- 239000000661 sodium alginate Substances 0.000 claims abstract description 4
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 4
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 3
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 3
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 3
- 150000001768 cations Chemical class 0.000 claims abstract description 3
- 239000004014 plasticizer Substances 0.000 claims abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 235000010492 gellan gum Nutrition 0.000 claims description 3
- 239000000216 gellan gum Substances 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 13
- 239000002775 capsule Substances 0.000 abstract description 10
- 235000019198 oils Nutrition 0.000 abstract description 10
- 239000001993 wax Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 235000019484 Rapeseed oil Nutrition 0.000 abstract description 3
- 235000013871 bee wax Nutrition 0.000 abstract description 3
- 239000012166 beeswax Substances 0.000 abstract description 3
- 239000004203 carnauba wax Substances 0.000 abstract description 2
- 235000013869 carnauba wax Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 4
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 244000258044 Solanum gilo Species 0.000 abstract 1
- 229940092738 beeswax Drugs 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 8
- 239000003921 oil Substances 0.000 description 6
- 230000037406 food intake Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QSTURKXDYNIRGT-UHFFFAOYSA-N 2-hydroxydec-2-enoic acid Chemical compound CCCCCCCC=C(O)C(O)=O QSTURKXDYNIRGT-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000003631 expected effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 240000004668 Valerianella locusta Species 0.000 description 2
- 235000003560 Valerianella locusta Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006198 methoxylation reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
Landscapes
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は主として、長期間保存しても安定で且つ摂取後
１期待通りの効果を発現し得るローヤルゼリー食品に於
けるローヤルゼリー軟カプセルに関するものである。Detailed Description of the Invention (Field of Industrial Application) The present invention mainly relates to a royal jelly soft capsule in a royal jelly food that is stable even when stored for a long period of time and can exhibit the expected effects after ingestion. be.
（従来の技術）
ローヤルゼリーは古くより知られた栄養補助食品であり
、今日でも強精強壮剤として根強い人気を有している。(Prior Art) Royal jelly is a nutritional supplement that has been known for a long time, and even today it remains popular as a tonic.
市販されているローヤルゼリーは採取したそのままの
形で製品化された生ローヤルゼリー生ローヤルゼリー中
の水分のみを除去し粉末状にした乾燥ローヤルゼリー、
生または乾燥ローヤルゼリーに１原材料、添加物を使っ
て調製した調製ローヤルゼリーに大別され、一般には新
鮮な生ローヤルゼリーが他の形のローヤルゼリーに比べ
、元来ローヤルゼリーが有する効力が最も高いと言われ
ている。Commercially available royal jelly is raw royal jelly that is made into a product in the same form as it was harvested, dried royal jelly that is made into a powder by removing only the water content from raw royal jelly,
Royal jelly is broadly divided into fresh or dried royal jelly and prepared royal jelly prepared using one raw material and additives, and it is generally said that fresh royal jelly has the highest potency compared to other forms of royal jelly. There is.
然しながら、生ローヤルゼリーは非常に不安定なもので
あって熱に弱く、紫外線及び酸素に短時間ふれても変質
する為、取扱いが面倒であり、又、保管、流通面でコス
トがかかり過ぎる欠点がある。However, raw royal jelly is extremely unstable, sensitive to heat, and deteriorates even if exposed to ultraviolet rays and oxygen for a short period of time, making it difficult to handle and costly in terms of storage and distribution. be.
そこで生ローヤルゼリーの欠点である保存安定性を改良
すべく゛考えだされたのが、乾燥ローヤルゼリー及び調
製ローヤルゼリーであり、なかでも比較的保存安定性が
良いものに、生又は乾燥ローヤルゼリーを食用油中に懸
濁してゼラチン皮膜で被覆したローヤルゼリー軟カプセ
ルとサイクロデキストリンで生ローヤルゼリーを混練し
て包接した後、粉末化する方法がある。Therefore, dried royal jelly and prepared royal jelly were devised to improve the storage stability, which is a shortcoming of fresh royal jelly.Among these, dried royal jelly and prepared royal jelly have relatively good storage stability. There is a method of kneading raw royal jelly with cyclodextrin and a royal jelly soft capsule that has been suspended and coated with a gelatin film to clathrate it, and then powdering it.
（発明は解決しようとする課ＩＩ）
ところが、乾燥ローヤルゼリーや調製ローヤルゼリーは
何れも生ローヤルゼリーに比べて一長一短があって加工
に費用が嵩む割には十分な効果は得られない、 何故な
ら、これらのローヤルゼリー加工物は加工段階での効力
の低下が避けられず、しかも保存中の変質や効果の減退
について生ローヤルゼリーはとではないにしても完全に
これをおさえているわけではないからである。 例えば
、従来技術中で比較的保存安定性が良いものとして述べ
たローヤルゼリー軟カプセルは、ローヤルゼリーが食用
油中に封入サレる為、酸素とローヤルゼリーとの接触に
よる劣化、又湿気によるローヤルゼリーの劣化には効果
があるが室温保存による経時的安定性が十分ではない更
に又、サイクロデキストリンで生ローヤルゼリーを包接
する方法は密閉容器中では室温保存でも比較的安定であ
るが、開封下においては粉末である為、酸素と接触し易
く、又吸湿し易い為不安定であった又、従来のすべての
ローヤルゼリー製品はあくまで保存安定性を主眼とし、
調製ローヤルゼリーにみられる錠剤型、カプセル型の製
品においても、これに摂取し易さを加味したものに過ぎ
ず、ローヤルゼリーが胃液にて分解し、効力の発現に著
るしい低下を及ぼすことを解決しようとした製品はなか
った。(Question II that the invention aims to solve) However, both dried royal jelly and prepared royal jelly have advantages and disadvantages compared to fresh royal jelly, and they do not provide sufficient effects despite the high cost of processing. This is because processed royal jelly products inevitably suffer from a decrease in efficacy during the processing stage, and even though raw royal jelly does not, it does not completely prevent deterioration and loss of effectiveness during storage. For example, royal jelly soft capsules, which are described as having relatively good storage stability in the prior art, are encapsulated in edible oil, so they do not deteriorate due to contact between oxygen and royal jelly, or due to moisture. Although it is effective, the stability over time when stored at room temperature is not sufficient.Furthermore, the method of including raw royal jelly with cyclodextrin is relatively stable even when stored at room temperature in a closed container, but it is a powder when opened. However, all conventional royal jelly products focused on storage stability;
Tablet-shaped and capsule-shaped products such as those found in prepared royal jelly are simply a product with the added benefit of ease of ingestion, and this solves the problem of royal jelly decomposing in gastric juices, which significantly reduces the expression of efficacy. There was no product that I tried.
而して、本発明はこれらの状況をふまえて保存安定性が
従来のどのローヤルゼリー製品よりも安定で且つ摂取後
ローヤルゼリーの胃液での分解を防ぎ、期待通りの効果
を発現し得るローヤルゼリー食品を提供することを目的
とするものである。Therefore, in view of these circumstances, the present invention provides a royal jelly food that is more stable in storage than any conventional royal jelly product, prevents royal jelly from being decomposed in gastric juice after ingestion, and exhibits the expected effects. The purpose is to
（課題を解決するための手段）
前記問題点を解決するために本発明者が鋭意研究した結
果、前述した欠点をもつａ−ヤルゼリーのサイクロデキ
ストリン包接物を硬化油又はロウ中に懸濁し、ゼラチン
軟カプセル化すれば酸化及び湿度、温度の影響よりロー
ヤルゼリーが守られ、保存性が大幅に向上することを見
い出した。 この場合、硬化油とは常温で固体であるも
のを言い、具体的にはナタネ硬化油、大豆硬化油、牛脂
硬化油等である。(Means for Solving the Problems) As a result of intensive research by the present inventors in order to solve the above-mentioned problems, the cyclodextrin clathrate of a-yal jelly, which has the above-mentioned drawbacks, is suspended in hydrogenated oil or wax, It has been found that encapsulating royal jelly in soft gelatin capsules protects it from the effects of oxidation, humidity, and temperature, and greatly improves its shelf life. In this case, hydrogenated oil refers to one that is solid at room temperature, and specifically includes hydrogenated rapeseed oil, hydrogenated soybean oil, hydrogenated beef tallow oil, and the like.
又、ロウとはカルナバロウのような植物ロウ又はミツロ
ウのような動物ロウである。 更に、この時、軟カプセ
ル皮膜基剤として、ゼラチン、グリセリンの他に２価以
上の陽イオンで架橋して硬化する水溶性多糖類及び炭酸
カルシウム塩を主成分とする天然カルシウムを配合すれ
ば該軟カプセルが人に摂取され、胃に入った瞬間に天然
力ルシヴム中のカルシウムイオンが胃酸によって放出さ
れ、瞬時にしてこの架橋性多糖類が硬化して胃液中では
溶解せず腸内では容易にとけるカプセル皮膜を形成する
のである。Further, the wax is a vegetable wax such as carnauba wax or an animal wax such as beeswax. Furthermore, at this time, if a water-soluble polysaccharide that is cross-linked and hardened with divalent or higher cations and natural calcium whose main components are calcium carbonate salt are added to the soft capsule film base in addition to gelatin and glycerin, the gelatin and glycerin can be added. When a soft capsule is ingested by a person and enters the stomach, the calcium ions in the natural lucivum are released by gastric acid, and the crosslinked polysaccharide instantly hardens and does not dissolve in the gastric fluid but easily enters the intestines. It forms a capsule film that dissolves.
この場合の架橋性多糖類とは、アルギン酸ナトリウム、
ジェランガム、低メトキシルペクチンであり。In this case, the crosslinked polysaccharide is sodium alginate,
Gellan gum is low in methoxyl pectin.
このいずれでも良い、 但し、配合量はアルギン酸ナト
リウムの場合、使用するゼラチンに対し２〜５毛峻部が
望ましく、ジェランガムは該ゼラチンに対し０．５〜１
重量部が望ましい。 又、低メトキシルペクチンは分子
量１０００００〜２０００００、メトキシル化度３〜５
％のもので、該ゼラチンに対し１０〜１５重量部が望ま
しい。Any of these may be used; however, in the case of sodium alginate, it is preferable to use 2 to 5 hairs per gelatin, and for gellan gum, it is preferably 0.5 to 1 part per gelatin.
Parts by weight are preferred. In addition, low methoxyl pectin has a molecular weight of 100,000 to 200,000 and a degree of methoxylation of 3 to 5.
%, preferably 10 to 15 parts by weight based on the gelatin.
又、炭酸カルシウムを主成分とする天然カルシウムとは
、卵殻、貝殻、牛骨粉等であり、そのいずれでも良い、
胃液不溶性である該カプセル皮膜は胃液を通すが内容
物のローヤルゼリーは硬化油又はロウにて固定されてい
るため胃液のローヤルゼリーへの接触はカプセル表面部
分にしかすぎず、ローヤルゼリーの分解は防がれるので
ある。 又、該天然カルシウムはカプセル皮膜中にて遮
光性をもつため、保存時に於ける紫外線が起因する処の
ローヤルゼリーの劣化を防ぐ、 更に、該ローヤルゼリ
ーのカプセル皮膜に硬化油又はロウにてコーティングを
ほどこすと、保存時の耐酸化性、耐湿度性、又摂取時の
耐胃液性が向上されるのである。この場合の硬化油又は
ロウは前述のローヤルゼリーを内容物中に固定し得るも
のと同等で良い。In addition, natural calcium whose main component is calcium carbonate includes eggshells, shells, beef bone powder, etc., and any of them may be used.
The capsule membrane, which is insoluble in gastric juice, allows gastric juice to pass through, but since the royal jelly content is fixed with hydrogenated oil or wax, gastric juice comes into contact with the royal jelly only on the surface of the capsule, preventing the royal jelly from decomposing. It is. In addition, since the natural calcium has a light blocking property in the capsule film, it prevents the royal jelly from deteriorating due to ultraviolet rays during storage.Furthermore, the capsule film of the royal jelly can be coated with hydrogenated oil or wax. Straining improves oxidation resistance and humidity resistance during storage, and resistance to gastric juices during ingestion. The hydrogenated oil or wax in this case may be the same as that capable of fixing the aforementioned royal jelly in the contents.
以上の技術により、従来にない極めて安定なローヤルゼ
リー食品を得ることに成功したのである。Using the above technology, we succeeded in obtaining an extremely stable royal jelly food that has never existed before.
（実施例） 次いで図面により本発明の実施例を述べる。(Example) Next, embodiments of the present invention will be described with reference to the drawings.
生ローヤルゼリー １００部
サイクロデキストリン ７０部
精製水 ２０部
上記処方物を混練し凍結乾燥及び微粉細してローヤルゼ
リーサイクロデキストリン包接物を得た。Raw royal jelly 100 parts cyclodextrin 70 parts Purified water 20 parts The above formulation was kneaded, freeze-dried and pulverized to obtain a royal jelly cyclodextrin clathrate.
又、この時と同じ生ローヤルゼリーをそのまま凍結乾燥
し微粉細しで乾燥ローヤルゼリーを得た。In addition, the same raw royal jelly as used at this time was directly freeze-dried and pulverized to obtain dried royal jelly.
これらのローヤルゼリー加工物を内容物とした次の３種
類の軟カプセル処方を設定し、ロータリー式軟カプセル
製造装置を用いて常法によりオパール７゜５型の軟カプ
セルを成形した。 この時、これら３種の軟カプセルは
共に内容物量３６０ｍｇであり、内容するローヤルゼリ
ーは生ローヤルゼリーとして１５０ｍｇに相当するべく
調製した。The following three types of soft capsule formulations containing these processed royal jelly products were prepared, and opal 7.5 type soft capsules were molded by a conventional method using a rotary soft capsule manufacturing apparatus. At this time, each of these three types of soft capsules had a content amount of 360 mg, and the royal jelly content was prepared to correspond to 150 mg of raw royal jelly.
処方１（対照とするローヤルゼリー軟カプセル）皮膜処
方 内容物処方
ゼラチン １００重量部 乾燥ローヤルゼリー５２．５
グリセ リ ン ３０ｆＥ ｉｔ 部 ステ７リ
シ 酸モノヴリセライド ２５精製氷 ９０重
量部 ミツロー ２５コーンサラダ° ２
５７．５
３８０部ｇ
処方２（ローヤルゼリーＣＤ包接物を内容したローヤル
ゼリー軟カプセル）
ゼラチン １００重量部 ａ−ヤＡ！９−ＣＤ包接物
１５７．５グリセ リ ン ３０重１ｍ ステア
リン 酸モノラリセライト １５精製氷 ９０
重量部 ミツロー １５コーンサラダ油
１７３．５
８０ｍｇ
処方３（本発明によるローヤルゼリー軟カプセル）ゼラ
チン １００重量部 ａ−セル１ｙ−ｃｏ包接物 １５
７．５グリセリン ３０重量部 ナタネ硬化油
２００卵殻末 ３０重量部 −レシチン
２，５フルイン酸ナトリウム ５重Ｊｉ 部
３６０ｍｇ精製水
１１０重量部
処方１，２．３の軟カプセルについて次の試験を行った
後、各検体の内容ローヤルゼリーの変色度合の観察及び
内容ローヤルヤリ−中のヒドロキシデセン酸の定量によ
って内容ローヤルセリ−の効力を推察した。Formulation 1 (Royal jelly soft capsule as a control) Film formulation Contents formulation Gelatin 100 parts by weight Dried royal jelly 52.5
Glycerin 30 fE it part Ste7 Liric acid monovriceride 25 Purified ice 90 parts by weight Beeswax 25 Corn salad° 2
57.5 380 parts g Prescription 2 (Royal jelly soft capsule containing royal jelly CD clathrate) Gelatin 100 parts by weight a-ya A! 9-CD inclusion
157.5 Glycerin 30 weight 1m Stearic acid monoralycerite 15 Purified ice 90
Weight part: Beeslo 15 Corn salad oil
173.5 80 mg Formulation 3 (royal jelly soft capsule according to the present invention) Gelatin 100 parts by weight a-cell 1y-co clathrate 15
7.5 Glycerin 30 parts by weight Hydrogenated rapeseed oil
200 eggshell powder 30 parts by weight - lecithin
Sodium 2,5 fluinate 5-Ji part
360mg purified water
After conducting the following test on soft capsules with 110 parts by weight of formulations 1, 2.3, the efficacy of the royal jelly content was estimated by observing the degree of discoloration of the royal jelly content in each sample and quantifying the hydroxydecenoic acid content in the royal jelly content. did.
（試 験）
ｌ、直射日光上保存試験
処方ｌ、２．３の軟カプセルを６号ガラス製サップルピ
ンに１０カプセルずつ入れ密栓し、直射日光下に８時〜
１７時まで、のへ１０日間保存した。(Test) 1. Storage under direct sunlight Test formulation 1. Place 10 capsules each of the soft capsules of 2.3 into No. 6 glass supple pins, seal tightly, and store under direct sunlight from 8 o'clock.
It was stored for 10 days until 5 p.m.
２、加温下保存試験
処方ｌ、２．３の軟カプセルを６号カラス製サンプルビ
ンに１０カプセルずつ入れ密栓し、５０１″Ｃ恒温槽に
１０日間保存した。2. Storage under heating Test Formulation 1. Ten capsules each of the soft capsules of 2.3 were placed in a No. 6 glass sample bottle, sealed tightly, and stored in a 501''C constant temperature bath for 10 days.
３、加湿下保存試験
処方１，２．３の軟カプセルを６号ガラス製サンプルビ
ンに１０カプセルずつ入れ、栓をせずに３０’Ｃ１００
％ＲＨ恒温槽にｌＯ日間保存した。3. Humidified storage test Put 10 soft capsules of formulations 1 and 2.3 into a No. 6 glass sample bottle and bottle at 30'C100 without capping.
It was stored in a %RH constant temperature bath for 10 days.
４、崩壊試験
処方１，２．３の軟カプセルについて日本薬局方の崩壊
試験法に基き、崩壊試験を行った。4. Disintegration test A disintegration test was conducted on the soft capsules of formulations 1 and 2.3 based on the disintegration test method of the Japanese Pharmacopoeia.
（結 果） 試験１〜３の結果を次に示す。(Result) The results of Tests 1 to 3 are shown below.
試験４の結果を次に示す。The results of Test 4 are shown below.
供試カプセル数：６個
処方１ 人工胃液中において３．５分で内容物が流出し
はじめ、８．５分で完全に崩壊した。Number of capsules tested: 6 Prescription 1 The contents began to flow out in 3.5 minutes in artificial gastric juice, and completely disintegrated in 8.5 minutes.
（６個の平均）
処方２ 人工胃液中において３．５分で内容物が流出し
はじめ、８．５分で完全に崩壊した。(Average of 6 samples) Prescription 2 The contents began to flow out in 3.5 minutes in artificial gastric juice, and completely disintegrated in 8.5 minutes.
処方３ 人工胃液中において２時間後にも内容液は流出
せず、人工腸液中で５分で内容液が流出し、１５．４分
後には完全に崩壊した。Prescription 3 The content fluid did not flow out even after 2 hours in artificial gastric fluid, the content fluid flowed out in 5 minutes in artificial intestinal fluid, and completely disintegrated after 15.4 minutes.
又、処方ｌ及び処方２について崩壊試験後の人工胃液中
のヒドロキシデセン酸量を定量した。 又、処方３に
ついては崩壊試験後の人工腸液中のヒドロキシデセン酸
量を定量した。Furthermore, for Formulation 1 and Formulation 2, the amount of hydroxydecenoic acid in the artificial gastric fluid after the disintegration test was determined. For Formulation 3, the amount of hydroxydecenoic acid in the artificial intestinal fluid after the disintegration test was determined.
ヒドロキシデセン酸量（％）
処方１ ０．０５
処方２ ０．０５
処方３ ０．４５
以上の結果より本発明のローヤルゼリー軟カプセルは直
射日光下、加温下、加湿下において安定性に優れ且つ胃
液中でも効果の低下が少ないことが証明された。Amount of hydroxydecenoic acid (%) Formulation 1 0.05 Formulation 2 0.05 Formulation 3 0.45 From the above results, the royal jelly soft capsules of the present invention have excellent stability under direct sunlight, heating, and humidification, and are resistant to gastric fluid. Among them, it was proven that the decrease in effectiveness was small.
（発明の効果）
本発明により従来ローヤルゼリーが劣化するといわれた
さまざまな条件下において長期安定となり、又摂取後、
ローヤルゼリーの背中での分解をふせぎ、期待通りの効
果を発現し得る。(Effects of the invention) According to the present invention, royal jelly becomes stable for a long period of time under various conditions that were said to deteriorate conventionally, and after ingestion,
It prevents the decomposition of royal jelly on the back and produces the expected effects.
図面は本発明品の一部縦断した斜視図である。 特許出願人 富士カプセル株式会社 The drawing is a partially vertical perspective view of the product of the present invention. Patent applicant: Fuji Capsule Co., Ltd.
Claims (5)
を硬化油又はロウ中で固定して内容物と成し、ゼラチン
及び二価以上の陽イオンで架橋する架橋性多糖類、可塑
剤、天然カルシウムから成る皮膜中に前記内容物を封入
すると共に硬化油又はロウにて該皮膜表面を被覆するこ
とを特徴とするローヤルゼリー軟カプセル(1) Royal jelly clathrated with cyclodextrin is fixed in hydrogenated oil or wax to form the content, and a film is made of gelatin, a crosslinkable polysaccharide crosslinked with divalent or higher cations, a plasticizer, and natural calcium. A royal jelly soft capsule, characterized in that the above-mentioned contents are encapsulated therein and the surface of the film is coated with hydrogenated oil or wax.
請求項１記載のローヤルゼリー軟カプセル(2) The royal jelly soft capsule according to claim 1, wherein the crosslinkable polysaccharide is sodium alginate.
請求項１記載のローヤルゼリー軟カプセル(3) The royal jelly soft capsule according to claim 1, wherein the crosslinkable polysaccharide is low methoxyl pectin.
記載のローヤルゼリー軟カプセル(4) Claim 1, wherein the crosslinkable polysaccharide is gellan gum.
Royal jelly soft capsules listed
とする卵殻、貝殻、牛骨粉等の天然カルシウム剤である
請求項１記載のローヤルゼリー軟カプセル(5) The royal jelly soft capsule according to claim 1, wherein the natural calcium is a natural calcium agent such as eggshell, seashell, or beef bone powder containing calcium carbonate as a main component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2142746A JPH0436159A (en) | 1990-05-31 | 1990-05-31 | Royal jelly-containing soft capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2142746A JPH0436159A (en) | 1990-05-31 | 1990-05-31 | Royal jelly-containing soft capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0436159A true JPH0436159A (en) | 1992-02-06 |
Family
ID=15322615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2142746A Pending JPH0436159A (en) | 1990-05-31 | 1990-05-31 | Royal jelly-containing soft capsule |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0436159A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002017886A1 (en) * | 2000-09-01 | 2002-03-07 | Warner-Lambert Company Llc | Pectin film compositions |
| JP2006314283A (en) * | 2005-05-13 | 2006-11-24 | Yawata Bussan Kk | Royal jelly-containing capsule and method for producing the same |
| JP2009028544A (en) * | 1997-02-24 | 2009-02-12 | Fuji Capsule Kk | Soft capsule |
| WO2010146845A1 (en) * | 2009-06-19 | 2010-12-23 | 富士カプセル株式会社 | Soft capsule and manufacturing method therefor |
| US9456991B2 (en) | 2011-12-22 | 2016-10-04 | Erik Baes | Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof |
| WO2019221078A1 (en) * | 2018-05-18 | 2019-11-21 | 株式会社山田養蜂場本社 | Stabilization of enzyme-degraded royal jelly |
| KR20200031811A (en) * | 2018-09-17 | 2020-03-25 | 안창기 | Composition for Preventing or Treating Diabetes Comprising Beeswax-Coated Bee Venom Beads As Active Ingredient |
-
1990
- 1990-05-31 JP JP2142746A patent/JPH0436159A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4638927B2 (en) * | 1997-02-24 | 2011-02-23 | 富士カプセル株式会社 | Soft capsule |
| JP2009028544A (en) * | 1997-02-24 | 2009-02-12 | Fuji Capsule Kk | Soft capsule |
| WO2002017886A1 (en) * | 2000-09-01 | 2002-03-07 | Warner-Lambert Company Llc | Pectin film compositions |
| US7041315B2 (en) | 2000-09-01 | 2006-05-09 | Warner Lambert Company | Pectin film compositions |
| AU2002210449B2 (en) * | 2000-09-01 | 2006-10-26 | Warner-Lambert Company Llc | Pectin film compositions |
| EA007563B1 (en) * | 2000-09-01 | 2006-12-29 | Варнер-Ламберт Компани Ллс | Pectin film composition |
| JP4529047B2 (en) * | 2005-05-13 | 2010-08-25 | 八幡物産株式会社 | Royal jelly-containing capsule and method for producing royal jelly-containing capsule |
| JP2006314283A (en) * | 2005-05-13 | 2006-11-24 | Yawata Bussan Kk | Royal jelly-containing capsule and method for producing the same |
| WO2010146845A1 (en) * | 2009-06-19 | 2010-12-23 | 富士カプセル株式会社 | Soft capsule and manufacturing method therefor |
| JP4822299B2 (en) * | 2009-06-19 | 2011-11-24 | 富士カプセル株式会社 | Soft capsule and method for producing the same |
| JP2012001553A (en) * | 2009-06-19 | 2012-01-05 | Fuji Capsule Kk | Soft capsule and manufacturing method therefor |
| JP2017039724A (en) * | 2009-06-19 | 2017-02-23 | 富士カプセル株式会社 | Soft capsule and method for producing the same |
| US9456991B2 (en) | 2011-12-22 | 2016-10-04 | Erik Baes | Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof |
| WO2019221078A1 (en) * | 2018-05-18 | 2019-11-21 | 株式会社山田養蜂場本社 | Stabilization of enzyme-degraded royal jelly |
| KR20200031811A (en) * | 2018-09-17 | 2020-03-25 | 안창기 | Composition for Preventing or Treating Diabetes Comprising Beeswax-Coated Bee Venom Beads As Active Ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4693085B2 (en) | Prebiotic and probiotic compositions and methods of using them in intestinal based therapy | |
| Brown et al. | The effect of pectin on the structure and function of the rat small intestine | |
| EP0952824B1 (en) | Enteric coating, comprising alginic acid, for an oral preparation | |
| ES2708811T3 (en) | Procedure for the manufacture of soft enteric capsule | |
| FI84874B (en) | FOERFARANDE FOER INKAPSLING AV BIOLOGISKT AKTIVA AEMNEN, ENLIGT METODEN FRAMSTAELLD KAPSEL, DESS ANVAENDNING OCH FODER INNEHAOLLANDE DEN. | |
| CN100539874C (en) | A kind of fresh spirulina nutrient solution and preparation method thereof | |
| JPH02502908A (en) | antacid composition | |
| JP4755633B2 (en) | Pharmaceutical composition containing pectin and phospholipid used as an antidiarrheal agent and an anti-ulcer agent | |
| JPH0436159A (en) | Royal jelly-containing soft capsule | |
| TW202233165A (en) | Delayed release softgel capsules | |
| JP3712394B2 (en) | Cactiaceae-based formulations with fat-coagulating properties and methods for obtaining such formulations | |
| Wang et al. | Preparing, optimising, and evaluating chitosan nanocapsules to improve the stability of anthocyanins from Aronia melanocarpa | |
| JPS61151127A (en) | Production of soft capsule containing bifidus bacteria | |
| EA029505B1 (en) | Compositions based on clay and bee pollen, method for preparing same, and nutritional and therapeutic uses thereof | |
| KR20210123989A (en) | Method for producing soft capsule type functional health food | |
| JPS58175449A (en) | Feed additive composition for ruminant | |
| JP2872635B2 (en) | healthy food | |
| JP2578460B2 (en) | Multifunctional food and its manufacturing method | |
| JPH05238945A (en) | Intestinal environment-improving agent | |
| WO1989005630A1 (en) | Oral dosage units for pharmaceuticals and their use and preparation | |
| ES2812148T3 (en) | Preparation for body weight control based on chitosan and cellulose | |
| EP1407677B1 (en) | Compositions comprising partly-hydrolized fish gelatin and use thereof | |
| CN215460355U (en) | High-activity probiotic crystal ball containing enzymolysis-resistant starch matrix | |
| JP2007518695A (en) | Compositions and methods for treating gastrolith and hair gastrolith | |
| JP3059126U (en) | Capsules with royal jelly |